Eric Huselton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8807369/publications.pdf

Version: 2024-02-01

	1684188	1474206
76	5	9
citations	h-index	g-index
18	18	106
docs citations	times ranked	citing authors
	citations 18	76 5 citations h-index 18 18

#	Article	IF	CITATIONS
1	Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Leukemia and Lymphoma, 2022, 63, 222-226.	1.3	O
2	A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms. Blood Advances, 2022, 6, 3850-3860.	5.2	13
3	Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2). Journal of Geriatric Oncology, 2022, 13, 545-553.	1.0	2
4	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 2021, 62, 1441-1449.	1.3	2
5	A Case of Acute Eosinophilic Leukemia with a Novel PHF6 Mutation. Case Reports in Hematology, 2021, 2021, 1-4.	0.4	O
6	Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes. Blood Advances, 2021, 5, 5554-5564.	5. 2	4
7	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research, 2021, 110, 106713.	0.8	9
8	Synchronous B-Cell Acute Lymphoblastic Leukemia and Serous Ovarian Carcinoma: A Case Report. Case Reports in Oncology, 2021, 14, 1621-1626.	0.7	0
9	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	1.4	O
10	Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood, 2020, 136, 20-21.	1.4	1
11	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3776-3783.	7. O	14
12	Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide. Blood, 2019, 134, 4496-4496.	1.4	2
13	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. Blood, 2019, 134, 3915-3915.	1.4	6
14	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2047-2055.	2.0	18
15	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 769-771.	2.4	3
16	Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated with Similar Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, S279.	2.0	1
17	Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS. Blood, 2016, 128, 2278-2278.	1.4	0